Evotec AG (NASDAQ:EVO) Receives Consensus Recommendation of “Hold” from Analysts

Evotec AG (NASDAQ:EVO) has been assigned a consensus rating of “Hold” from the five analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $7.00.

Several equities analysts have recently weighed in on EVO shares. Berenberg Bank assumed coverage on shares of Evotec in a report on Tuesday, February 3rd. They set a “buy” rating for the company. Wall Street Zen upgraded shares of Evotec from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a report on Monday, December 29th.

Hedge Funds Weigh In On Evotec

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE raised its holdings in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares during the period. Envestnet Asset Management Inc. acquired a new stake in Evotec in the second quarter valued at approximately $385,000. XTX Topco Ltd purchased a new stake in shares of Evotec in the second quarter valued at approximately $66,000. Marshall Wace LLP acquired a new position in shares of Evotec during the 2nd quarter worth approximately $169,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after buying an additional 4,600 shares during the period. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Stock Down 1.7%

Shares of NASDAQ:EVO opened at $2.34 on Wednesday. Evotec has a 12-month low of $2.31 and a 12-month high of $4.80. The business has a 50 day moving average of $3.26 and a two-hundred day moving average of $3.39. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.12 and a quick ratio of 2.03.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.